Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery

    November 2025 in “ Journal of Medicinal Chemistry
    Laura Gioiello, Rita Maria Concetta Di Martino, Tracey Pirali
    TLDR Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
    The document explores the potential of PROTACs (proteolysis-targeting chimeras) for topical delivery, particularly in treating androgenetic alopecia (AGA) and other skin conditions. PROTACs offer a novel approach by degrading disease-relevant proteins, but face challenges like systemic toxicity and poor pharmacokinetics. Topical administration can mitigate these issues by localizing treatment and reducing systemic exposure. The development of microneedle technology enhances skin penetration of PROTACs, with promising preclinical results for hair regrowth. Clinical trials for PROTACs targeting androgen receptors for AGA and acne show potential for effective and safe topical treatments. The document also discusses PROTACs for atopic dermatitis and pigmentary disorders, highlighting their advantages in minimizing systemic side effects and enhancing treatment efficacy. Challenges remain in drug delivery, stability, and skin permeability, but innovative delivery systems like microneedles offer promising solutions.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 46 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  135 upvotes 1 year ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Is GT20029 supposed to regrow hair as well?

      in Treatment  9 upvotes 2 years ago
      The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

      community Silicon Valley backed company aims to cure hair loss

      in Technology  54 upvotes 3 years ago
      A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

      community bro where tf is GT20029, Q1 2024 is over already

      in Research/Science  40 upvotes 1 year ago
      The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

      community Kintor does not have abandoned KX-826 - ANNUAL RESULTS 2023

      in Product  7 upvotes 1 year ago
      The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

    Similar Research

    5 / 39 results